

NEUROCRINE BIOSCIENCES INC

Form 8-K

May 28, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of the earliest event reported): May 28, 2008**

**NEUROCRINE BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation or  
organization)

**0-22705**  
(Commission File  
Number)

**33-0525145**  
(IRS Employer  
Identification No.)

**12790 El Camino Real, San Diego, California**

(Address of principal executive offices)

**92130**

(Zip Code)

Registrant's telephone number, including area code: **(858) 617-7600**

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

**TABLE OF CONTENTS**

ITEM 8.01 OTHER EVENTS  
SIGNATURES

---

**Table of Contents****ITEM 8.01 OTHER EVENTS.**

The Company's Annual Meeting of Stockholders was held on May 28, 2008. As of the close of business on April 1, 2008, the record date for the Annual Meeting, there were 38,421,043 shares of common stock entitled to vote, of which there were 35,723,541 shares present at the Annual Meeting in person or by proxy. At the Annual Meeting, stockholders voted on five matters: (i) the election of two Class III Directors for a term of three years expiring at the 2011 Annual Meeting of Stockholders, (ii) the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2008, (iii) the approval of an amendment to the Company's 2003 Incentive Stock Plan, as amended, to increase the number of shares of common stock reserved for issuance thereunder from 4,800,000 to 5,300,000 shares, (iv) the consideration of a stockholder proposal to declassify the Board of Directors, and (v) the consideration of a stockholder proposal regarding an engagement process with the proponents of certain stockholder proposals. The voting results were as follows:

Election of two Class III Directors for a term of three years expiring at the 2011 Annual Meeting of Stockholders

Gary A. Lyons	For	27,218,907	Withheld	8,504,634
Kevin C. Gorman, Ph.D.	For	31,481,827	Withheld	4,241,714

The two nominees for Class III Director were elected. Our Class I Directors, Joseph Mollica, Ph.D, Wylie W. Vale, Ph.D. and W. Thomas Mitchell, continue in office until our 2009 Annual Meeting of Stockholders. Our Class II Directors, Corinne H. Lyle, Richard F. Pops, and Stephen A. Sherwin, continue in office until our 2010 Annual Meeting of Stockholders.

Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2008

For	34,388,279	Against	1,131,756	Abstain	203,506
-----	------------	---------	-----------	---------	---------

The appointment of Ernst & Young LLP was ratified.

Approval of an amendment to the Company's 2003 Incentive Stock Plan, as amended, which increases the number of shares of common stock reserved for issuance from 4,800,000 to 5,300,000 shares

For	15,678,162	Against	9,399,422	Abstain	109,986
-----	------------	---------	-----------	---------	---------

The amendment to the Company's 2003 Incentive Stock Plan, as amended, was approved.

Consideration of a stockholder proposal to declassify the Board of Directors

For	17,100,280	Against	8,011,694	Abstain	75,596
-----	------------	---------	-----------	---------	--------

The stockholder proposal was approved.

Consideration of a stockholder proposal regarding an engagement process with the proponents of certain stockholder proposals

For	13,941,016	Against	11,140,397	Abstain	106,157
-----	------------	---------	------------	---------	---------

The stockholder proposal was approved.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: May 28, 2008

NEUROCRINE BIOSCIENCES, INC.

/s/ TIMOTHY P. COUGHLIN

Timothy P. Coughlin  
Vice President and Chief Financial Officer